Vertex casually drops Orkambi revenue slowdown, creating
Por um escritor misterioso
Descrição
Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.
SEC Filing – Royalty Pharma
Motley Fool: Smart shopping, how dumb is it to gamble and this week's trivia
October, 2015
SEC Filing – Royalty Pharma
Vertex Reports First Quarter 2023 Financial Results
S-1/A
S-1/A
S-1
Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging
The Arbitrum airdrop: lessons in user acquisition and retention, by Cenit Finance, Cenit Finance, Oct, 2023
SEC Filing – Royalty Pharma
SEC Filing – Royalty Pharma
de
por adulto (o preço varia de acordo com o tamanho do grupo)
